NCT06140524 2026-04-08
LINKER-MGUS1
Regeneron Pharmaceuticals
Phase 2 Recruiting
Clinical Trials
7 trialsNCT04776395 2025-09-15
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Emory University
Phase 2 Recruiting
NCT06762769 2025-08-01
MODIFY
University College, London
Phase 2 Recruiting
NCT05469893 2025-04-24
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05597345 2025-02-10
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
University of Rochester
Phase 2 Recruiting
NCT06183489 2024-10-18
ERASMM
European Myeloma Network B.V.
Phase 2 Recruiting
NCT04731844 2024-07-12
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
University of Rochester
Phase 2 Recruiting